SAN DIEGO—(BUSINESS WIRE)—Jan. 25, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced the appointment of James (Randy) R. Owen,M.D., as Senior Vice President, Clinical Development and Chief MedicalOfficer. Dr. Owen will be responsible for evolving and executing theclinical development programs for ACADIA’s product candidates and reportto Serge Stankovic, M.D., M.S.P.H., ACADIA’s Executive Vice President,Head of Research and Development.
“Randy brings significant expertise in clinical research and developmentalong with a deep knowledge of CNS science,” said Steve Davis, ACADIA’sPresident and Chief Executive Officer. “He has led the development andapproval of important therapeutics in CNS and will be a valued additionto the ACADIA team as we seek to help patients who suffer from seriousneurological and psychiatric disorders.”
Dr. Owen most recently served as Vice President, U.S. Clinical Affairsat Lundbeck LLC from 2010 to 2016. During his tenure, his team ofmedical experts and scientists made significant contributions in drugdevelopment across a wide range of neurological and psychiatricdisorders, including innovative development programs in schizophrenia,Alzheimer’s disease and stroke, as well as pediatric and adult orphanindications. Prior to joining Lundbeck, Dr. Owen served as GroupDirector, Global Clinical Research at Bristol-Myers Squibb Company wherehe co-led the life-cycle management of Abilify® during aperiod of product extensions in psychiatric indications in the UnitedStates and Europe. Dr. Owen received his B.A. at Haverford College andhis M.D. at East Tennessee State University, Quillen College ofMedicine. He completed his residency at Emory University and is boardcertified in psychiatry.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has a pipeline of productcandidates led by NUPLAZID™ (pimavanserin), for which we have submitteda New Drug Application (NDA) in Parkinson’s disease psychosis to the FDAand which has the potential to be the first drug approved in the UnitedStates for this condition. The FDA has classified the NUPLAZID NDA ashaving Priority Review status. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial in schizophrenia. ACADIA also hasclinical-stage programs for glaucoma and, in collaboration withAllergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the potential for NUPLAZID(pimavanserin) to be the first drug approved in the United States forParkinson’s disease psychosis (PDP) and the potential timing of suchapproval, if approved at all, by the FDA; the potential contributions ofDr. Owen to ACADIA; the progress, timing and results of ACADIA’s drugdiscovery and development programs, either alone or with a partner,including the progress and expected timing of clinical trials; and thebenefits to be derived from ACADIA’s product candidates, includingpimavanserin. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization, and collaborations with others, and thefact that past results of clinical trials and past regulatory decisionsmay not be indicative of future trial results or future regulatorydecisions, respectively. For a discussion of these and other factors,please refer to ACADIA’s annual report on Form 10-K for the year endedDecember 31, 2014 as well as ACADIA’s subsequent filings with theSecurities and Exchange Commission. You are cautioned not to place unduereliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions ofthe Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director ofInvestor Relations
(858) 558-2871